Program
esreboxetine
Also written as “Esreboxetine”, “SS-RBX” and “AXS-14 (Esreboxetine)”.
Its studies are mostly in Fibromyalgia · Urinary Incontinence, Stress, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 60 open or running | phase 3since Nov 20, 2008 | Aug 26, 2005 | none ahead |
| Axsome Therapeutics | 22 open or running | phase 3since Feb 4, 2026 | Feb 4, 2026 | Mar 2028phase 3 · NCT07398417 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2005First studies: 2 phase 2 studies in Urinary Incontinence, StressNew to PfizerPfizer · NCT00138749, NCT00141128
- Sep 12, 2008Phase 2 study in FibromyalgiaPfizer · NCT00752505 · 89 enrolled · United States
- Nov 20, 2008Phase 3 study in FibromyalgiaPfizer · NCT00796601
- Dec 2, 20082 phase 1 studiesPfizer · NCT00800956, NCT00809289
- Feb 4, 2026Axsome Therapeutics's first study: phase 3 study in FibromyalgiaNew to Axsome TherapeuticsAxsome Therapeutics · NCT07398417 · 620 planned · United States
- Jun 4, 2026Phase 3 study in FibromyalgiaAxsome Therapeutics · NCT07637162 · 300 planned · United States
Ahead
- Mar 2028Primary completion: phase 3 study in FibromyalgiaAxsome Therapeutics · NCT07398417
- May 2028Primary completion: phase 3 study in FibromyalgiaAxsome Therapeutics · NCT07637162
TargetBeta
“Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC6A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| Bupropionrule | GlaxoSmithKline | phase 4 | 29 |
| dexmethylphenidaterule | cingulate-therapeutics | phase 4 | 14 |
| Levomilnacipranrule | AbbVie | phase 4 | 13 |
| Amphetaminerule | Tris Pharma | phase 4 | 8 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07637162Fibromyalgia · United States | 3 | By invitation | Axsome Therapeutics | May 2028 | 300 |
| NCT07398417Fibromyalgia · United States | 3 | Recruiting | Axsome Therapeutics | Mar 2028 | 620 |
| NCT00809289Fibromyalgia · Belgium | 1 | Completed | Pfizer | Jul 2009 | 40 |
| NCT00800956Healthy · United States | 1 | Completed | Pfizer | Feb 2009 | 4 |
| NCT00796601Fibromyalgia | 3 | Withdrawn | Pfizer | May 1, 2010 | 0 |
| NCT00752505Fibromyalgia · United States | 2 | Completed | Pfizer | Jun 2009 | 89 |
| NCT00141128Urinary Incontinence, Stress · Denmark | 2 | Completed | Pfizer | 18 | |
| NCT00138749Urinary Incontinence, Stress · United States, Canada | 2 | Completed | Pfizer | Aug 2006 | 402 |
How it is read
Names in the registry
- “Esreboxetine”, 3 entries
- “SS-RBX”, 2 entries
- “AXS-14 (Esreboxetine)”, 1 entry
- “AXS-14 (esreboxetine)”, 1 entry
- “esreboxetine”, 1 entry
Conditions, from the studies’ own filings
- Fibromyalgia, 5 studies
- Urinary Incontinence, Stress, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.